Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
136 hedge funds and large institutions have $437M invested in Aerie Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 38 reducing their positions, and 21 closing their positions.
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
32% more capital invested
Capital invested by funds: $332M → $437M (+$105M)
26% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 38
5% more funds holding
Funds holding: 129 → 136 (+7)
25% less call options, than puts
Call options by funds: $123K | Put options by funds: $163K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$12.4M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$7.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.63M |
| 4 |
LCS
Levin Capital Strategies
New York
|
+$4.77M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$3.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
-$12.7M |
| 2 |
Morgan Stanley
New York
|
-$6.81M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.34M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.71M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$3.9M |
AERI Hedge Fund Activity: Q1 2022 in Review
136 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q1 2022, worth a combined $437M — up 32% from $332M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AERI positions and 21 closed out — a net gain of 8 holders — while 48 added to existing stakes and 38 trimmed.
The largest buyer was UBS Group, adding an estimated $12.4M. The largest seller was William Blair Investment Management, exiting entirely with an estimated $12.7M sold.
- 136 institutional investors held Aerie Pharmaceuticals (AERI) as of Q1 2022, up from 129 in Q4 2021.
- Funds reported $437M of Aerie Pharmaceuticals stock for Q1 2022, up 32% quarter-over-quarter.
- 29 funds opened new Aerie Pharmaceuticals positions in Q1 2022 and 21 closed out, a net change of +8 holders.
- The largest Aerie Pharmaceuticals buyer in Q1 2022 was UBS Group, an estimated $12.4M added.
- The largest Aerie Pharmaceuticals seller in Q1 2022 was William Blair Investment Management, an estimated $12.7M sold.
Based on aggregated 13F filings for Q1 2022.